http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106336406-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate | 2016-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106336406-B |
| titleOfInvention | Having beta2Octahydropentalene derivatives with receptor agonistic and M receptor antagonistic activity and their medical use |
| abstract | Has beta 2 Octahydro cyclopentadiene derivative with receptor agonism and M receptor antagonism activity and application thereof in medicine, namely compound shown in general formula (I) or stereoisomer, hydrate, metabolite, solvate, pharmaceutically acceptable salt, eutectic or prodrug thereof, preparation method and application thereof in preparing medicine for treating airway obstruction diseases, wherein the compound shown in general formula (I) is Wherein the definition of each substituent is the same as that in the specification. |
| priorityDate | 2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 148.